AssetMark Inc
AMLX icon

AssetMark Inc’s Amylyx Pharmaceuticals AMLX Stock Holding History

AssetMark Inc’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$349 Buy
+12
New +$318 ﹤0.01% 3506

Other funds holding AMLX

Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
iA Global Asset Management
iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

AssetMark Inc's AMLX Position: Q3 2026 in Review

AssetMark Inc opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 12 shares worth $349. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings.

50 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • AssetMark Inc held 12 shares of Amylyx Pharmaceuticals worth $349 as of Q3 2026.
  • Amylyx Pharmaceuticals was a new AssetMark Inc position in Q3 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3506 holding.
  • 50 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.